Dynastat
- Dynastat Vaikuttava aine
- parekoksibi
- Muoto
- Injektiokuiva-aine ja liuotin; Injektiokuiva-aine
- Vahvuus
- 40 mg
What is this? Dynastat is a pain-relief medicine given as an injection. It contains the active substance parecoxib.
What's happening? There is a shortage of Dynastat injections in the EU. Supplies are running low or unavailable.
Does this affect me? If you need this medicine for pain relief, you may be affected. Check with your doctor or pharmacist.
What should I do? Ask your pharmacist or doctor about other pain-relief options while supplies are low.
🤖 Tämä selkeäsanainen yhteenveto on tuotettu viranomaisen ilmoituksesta tekoälyä käyttäen. Se on tarkoitettu yleisluontoiseen tiedottamiseen — ei lääkärinlausunto. Terveydestäsi päättäessäsi ota aina yhteyttä apteekkiin tai lääkäriin ja lue alla oleva virallinen lähde.
📋 Virallisen viraston tiedotteesta
Päivitetty 1 viikko sitten- Viimeksi päivitetty
- 04/12/2025
- Ensimmäisen kerran julkaistu
- 14/04/2025
- Lääkkeet, joihin vaikutus kohdistuu
- Dynastat
- Vaikutukset vahvuuksiin
- 40 mg
- Oletettu ratkaisu
- January 2026 in Malta February 2026 in Greece March 2026 in Cyprus and France July 2026 in Bulgaria and Norway
- Toimituksen lyhytaikainen tilanne
- Ongoing
- Vaihtoehtojen saatavuus
- Unknown
- Lääkemuodot, joihin vaikuttaa
- Powder and solvent for solution for injectionPowder for solution for injection
- Kansainvälinen yleisnimi (INN) tai yleinen nimi
- parecoxib
Sivun sisältö
Puutetiedot
There is a shortage of Dynastat in some Members States of the European Economic Area (EEA).
Dynastat is a medicine used in adults for the short-term relief of pain after an operation. It is given by injection into a vein or muscle.
For further information on the use of the medicine, please refer to the medicine’s overview page.
The shortage is due to a reduction in the production capacity of Dynastat, following a temporary shutdown of one of the company’s production lines. The company is prioritising supply to markets where shortages are considered critical, with no country in the EEA currently experiencing critical shortages. Although the affected line has now resumed production, the company will need time to meet the current demand for Dynastat in the EEA.
The shortage currently affects seven EEA countries where the product is marketed: Cyprus, Greece, Malta, Bulgaria, France, Germany and Norway. The shortage in the Netherlands and Iceland is now resolved.
The shortage is expected to last until:
- January 2026 in Malta;
- February 2026 in Greece;
- March 2026 in Cyprus and France;
- July 2026 in Bulgaria and Norway.
Other EEA countries are at risk of shortage and the above information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
In addition, the marketing authorisation holder is working to expedite and coordinate the distribution of Dynastat in a way that minimises the impact of shortages and is exploring options to increase its production.
- Before starting treatment, healthcare professionals should ensure that sufficient supplies of Dynastat are available.
- Doctors should consider other medicines for post-operative pain relief if Dynastat is not available in their country, taking into consideration local and national guidance.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- Before starting treatment, your doctor will ensure that sufficient supplies of Dynastat are available.
- If Dynastat is not available in your country, there may be alternative medicines available for pain control which your doctor can prescribe.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Lyhytaikainen puute
The shortage is due to a reduction in the production capacity of Dynastat, following a temporary shutdown of one of the company’s production lines. The company is prioritising supply to markets where shortages are considered critical, with no country in the EEA currently experiencing critical shortages. Although the affected line has now resumed production, the company will need time to meet the current demand for Dynastat in the EEA.
Vaikutusalueella olevat jäsenvaltiot
The shortage currently affects seven EEA countries where the product is marketed: Cyprus, Greece, Malta, Bulgaria, France, Germany and Norway. The shortage in the Netherlands and Iceland is now resolved.
The shortage is expected to last until:
- January 2026 in Malta;
- February 2026 in Greece;
- March 2026 in Cyprus and France;
- July 2026 in Bulgaria and Norway.
Other EEA countries are at risk of shortage and the above information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
Valvonta puutteesta
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
In addition, the marketing authorisation holder is working to expedite and coordinate the distribution of Dynastat in a way that minimises the impact of shortages and is exploring options to increase its production.
Suositus terveydenhuollon ammattilaisille
- Before starting treatment, healthcare professionals should ensure that sufficient supplies of Dynastat are available.
- Doctors should consider other medicines for post-operative pain relief if Dynastat is not available in their country, taking into consideration local and national guidance.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Suositukset potilaille ja hoitajille
- Before starting treatment, your doctor will ensure that sufficient supplies of Dynastat are available.
- If Dynastat is not available in your country, there may be alternative medicines available for pain control which your doctor can prescribe.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Avainasiat
- Medicines affected
- Dynastat
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- parecoxib
- Pharmaceutical forms affected
- Powder and solvent for solution for injection
- Powder for solution for injection
- Strengths affected
- 40 mg
- Availability of alternatives
- Unknown
Avainpäivät
- Expected resolution
- January 2026 in Malta
February 2026 in Greece
March 2026 in Cyprus and France
July 2026 in Bulgaria and Norway - First published
- Last updated
Lääketieteelliset tiedot
🔬 Lääketieteelliset / tekniset tiedot ammattilaisille
INN: parecoxib · Forms: Powder and solvent for solution for injection;Powder for solution for injection · Strengths: 40 mg · Alternatives: Unknown
Kaikki tämän sivun tiedot perustuvat virallisen viraston tiedotteeseen. Käännämme ja tiivistämme ne; emme lisää tai muokkaa faktoja.